For an adult patient requiring acute migraine rescue with a non‑vasoconstrictive option, which CGRP‑receptor antagonist (gepant) is recommended and what is the appropriate dosing?

CGRP Receptor Antagonists (Gepants) for Acute Migraine Rescue

CGRP receptor antagonists (gepants) should be reserved as third-line therapy for acute migraine rescue in adults who have failed or cannot tolerate combination therapy with a triptan plus NSAID or acetaminophen. 1

Recommended Gepants and Dosing

The 2025 American College of Physicians guideline identifies three FDA-approved gepants for acute migraine treatment 1:

• Rimegepant (orally disintegrating tablet available) 2
• Ubrogepant (50 mg or 100 mg tablets; maximum 200 mg within 48 hours) 3
• Zavegepant (nasal spray formulation) 1

Choice among these three gepants should be based on route of administration preference and cost, as comparative effectiveness data between individual gepants remains uncertain 1.

Treatment Algorithm Position

First-Line Therapy

Start with NSAID (naproxen, ibuprofen) or acetaminophen monotherapy at adequate doses 1

Second-Line Therapy

If inadequate response to first-line, add a triptan to the NSAID or acetaminophen (combination therapy with sumatriptan + naproxen or rizatriptan + acetaminophen provides high-certainty evidence for superior outcomes) 1

Third-Line Therapy (Gepants)

Only consider gepants when patients:

• Do not tolerate combination triptan + NSAID/acetaminophen therapy, OR
• Have inadequate response to combination therapy, OR
• Have contraindications to triptans (cardiovascular disease, uncontrolled hypertension) 1

Evidence Quality and Strength

The ACP guideline rates gepants with "weak for" recommendation due to uncertain comparative effectiveness data 1, 4. The VA/DoD 2024 guideline similarly provides a "weak for" recommendation for ubrogepant and rimegepant 4. This contrasts sharply with the "strong for" recommendation given to triptan + NSAID combination therapy, which has high-certainty evidence 1.

Why Gepants Are Not First-Line

The evidence base shows:

• Low-certainty evidence that triptan + NSAID combination may have favorable net benefit compared to gepant monotherapy 1
• Patient preference panels showed no preference for CGRP antagonists-gepants when other options were available 1
• Cost and benefits were the most important factors in patient decision-making, with gepants being significantly more expensive 1

Clinical Advantages of Gepants

Despite their third-line positioning, gepants offer important benefits:

• No vasoconstriction: Safe in patients with cardiovascular risk factors where triptans are contraindicated 5, 6
• No hepatotoxicity at therapeutic doses: Unlike first-generation gepants 3, 6
• Dual indication: Rimegepant is approved for both acute treatment and prevention 2, 7
• Can be combined with CGRP monoclonal antibodies: Safe for acute rescue in patients already on preventive CGRP mAbs 8, 9

Efficacy Data

Gepants demonstrate moderate efficacy:

• Number needed to treat of 13 for pain freedom at 2 hours for rimegepant and ubrogepant 4
• Effective for pain relief and most bothersome symptom resolution 2, 3
• Well-tolerated with mild adverse effects (primarily constipation and fatigue) 10, 6

Critical Caveats

Medication Overuse Headache

Monitor frequency of use—threshold for medication overuse headache with gepants is ≥10 days per month (same as triptans) 1

Not for Prevention (Except Specific Gepants)

Only rimegepant and atogepant are FDA-approved for migraine prevention; ubrogepant is not effective as preventive therapy 3, 10, 7

Avoid These Medications

Never use opioids or butalbital for acute migraine treatment 1

Practical Implementation

When prescribing gepants:

• Treat early at migraine onset for best efficacy 1
• Consider orally disintegrating formulation (rimegepant) for faster onset and patient convenience 2
• Use nasal zavegepant if severe nausea/vomiting limits oral absorption 1
• Prescribe less costly options first within the treatment algorithm 1